Skip to main content

Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer

Trial Status: Approved

This research study is studying racial and genetic biomarkers of response in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.

Inclusion Criteria

  • Histologically confirmed endometrial cancer * Stage I-IV disease regardless of grade * Underwent surgical staging including hysterectomy, bilateral oophorectomy, washings, and pelvic lymphadenectomy
  • Eligible and evaluated on GOG-0210 clinical trial, a Molecular Staging Study in Endometrial Cancer
  • Available frozen or formalin-fixed and paraffin-embedded normal tissue that is free of tumor cells and yields sufficient high-quality normal DNA for testing
  • Consented their specimens and clinical data to be collected and used in future studies
  • Self-declared African-American or Caucasian race


Gynecologic Oncology Group
Contact: Rodney Rocconi
Phone: 251-665-8000


I. To identify racial categorization as the proportion of genetic background of African-American or European-American women with endometrioid endometrial cancer (EEC).

II. To evaluate the association of racial genetic admixture with clinicopathologic variables and outcomes.


I. To compare the concordance between racial genetic admixture and self-designated race categorization.

OUTLINE: This is a multicenter study. Patients are stratified by race (African-American vs European-American) and disease stage (I vs II vs III vs IV).

DNA from archived frozen normal tissue samples is genotyped for the ancestry informative markers. Clinicopathological and demographic characteristics associated with each sample are also collected.

Trial Phase Phase NA

Trial Type Ancillary-correlative

Lead Organization
Gynecologic Oncology Group

Principal Investigator
Rodney Rocconi

  • Primary ID GOG-8022
  • Secondary IDs NCI-2011-02867, CDR0000684547
  • ID NCT01198171